Course 2: ALS Treatments

Tuesday, March 11, 2025, 12:00 AM - Friday, March 10, 2028, 11:59 PM


AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours)

This $30 course includes access to all learning materials and your CME certificate/transcript upon completion. Select "Launch Course" above, then "Register" to enroll in the course.

With an overall lifetime risk of 1 in 400 Americans, almost all healthcare professionals will care for persons with ALS during their career. While a cure for ALS is still elusive, there are many treatments that are known to improve both quantity and quality of life for persons with ALS. This presentation reviews the currently available disease-modifying therapies for ALS, as well as details on most common secondary symptoms and best practices in symptom management and multidisciplinary care.

To begin this course, make sure you are logged in to CloudCME and then select the Register button above.

This is the 2nd course in a 7 course series. The courses are designed to be taken in order.

Course 1: ALS Fundamentals: Pathophysiology, Prognosis, and Presentation
Course 2: ALS Treatments (this page)
Course 3: Advances in ALS Biology and Therapy
Course 4: Respiratory Care of Individuals with ALS
Course 5: ALS & Physical Therapy
Course 6: ALS & Occupational Therapy
Course 7: ALS Impacts on Speech, Language, & Swallowing

_________________________________________________________________________________________________________________

Watch Dr. Kenneth Isaacs's 2-minute introduction video (opens in new tab).

View all courses in the ALS Patient & Caregiver Series (opens in new tab).

The Steve Gleason Institute for Neuroscience is for patients and their families, and scientists, clinicians and educators who work together to improve quality of life for those with neurodegenerative disease. Ours is an environment for not only the patient, but for all of those whose lives are affected by these diseases – helping them navigate the many challenges they face. The talents of a diverse group of individuals and the way they are united toward common goals truly make us special. Integrating the three disciplines of clinical care, research and adaptive technology fosters the development of new technologies and treatments to improve the quality of life for those with neurodegenerative diseases and provide education and support for their caregivers and family.

The purpose of our continuing education series is to answer questions from gaps identified from both patients and families, as well as providers who are seeking not only answers to clinical questions, but patients and caregivers looking for well-informed, caring and empathetic practitioners. Our series will start with the basics on neurogenerative disease states such as ALS and others, discuss the issues of ableism and the effects this may have on patients and their care givers, and then continue to explore topics around adaptive technology, medications, care and well-being, and other topics identified by patients and providers.

1. Name the 3 available disease modifying therapies currently approved by the Food and Drug Administration (FDA) for ALS.
2. List the top three secondary symptoms persons with ALS endorse following diagnosis.
3. Describe the benefits of multidisciplinary specialty care for persons with ALS.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The Washington State University (WSU) Elson S. Floyd College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The WSU Elson S. Floyd College of Medicine designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Accessibility

WSU College of Medicine Continuing Medical Education (CME) is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Act of 2008. If you have needs that require accommodation please contact the CME Unit at [email protected]

WSU Notice of Nondiscrimination

Please visit the Office of Compliance and Civil Rights to view Washington State University's policies.

WSU Institutional Neutrality

At Washington State University, we are committed to fostering an environment where diverse ideas and perspectives can flourish. As such, the university will maintain a practice of neutrality and will not take a position on contentious political or social issues, except in rare circumstances. Please visit WSU's Office of the President for more information.

Disclaimer

The material presented in this continuing medical education program is being made available for educational purposes only. This material is not intended to represent the best or only methods or procedures appropriate for the medical situation discussed; rather the material is intended to present an approach, view, statement, or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. This program does not represent or speak on behalf of Washington State University and/ or Elson S. Floyd College of Medicine. Participants should carefully consider all available scientific data before acting on knowledge gained through this activity.

WSU CME Online Self-Paced Courses (Enduring Materials) Refund Policy

No refunds will be granted for online (enduring) courses. If you have extenuating circumstances and would like to request an exception to the refund policy, contact us at [email protected].

Mitigation of Relevant Financial Relationships

Washington State University Elson S. Floyd College of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.